- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05263934
Effekt og sikkerhet av Depemokimab sammenlignet med Mepolizumab hos voksne med tilbakefall eller refraktær eosinofil granulomatose med polyangiitt (EGPA) (OCEAN)
En 52-ukers, randomisert, dobbeltblind, dobbel-dummy, parallellgruppe, multisenter, ikke-inferioritetsstudie for å undersøke effektiviteten og sikkerheten til Depemokimab sammenlignet med Mepolizumab hos voksne med residiverende eller refraktær eosinofil granulomatose med polyangiitt (EGPA) ) Mottak av standardbehandling (SoC) terapi
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy.
Studieoversikt
Status
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
La Plata, Argentina, B1900
- GSK Investigational Site
-
San Miguel de Tucumán, Argentina, T4000
- GSK Investigational Site
-
-
-
-
-
Santo André, Brasil, 09060-870
- GSK Investigational Site
-
São Paulo, Brasil, 4023900
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 3A9
- GSK Investigational Site
-
Toronto, Ontario, Canada, M5T 3L9
- GSK Investigational Site
-
-
-
-
Colorado
-
Denver, Colorado, Forente stater, 80206
- GSK Investigational Site
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610
- GSK Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905-0001
- GSK Investigational Site
-
-
New York
-
New York, New York, Forente stater, 10021-4823
- GSK Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28211
- GSK Investigational Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15261
- GSK Investigational Site
-
-
-
-
-
Brest, Frankrike, 29609
- GSK Investigational Site
-
La Roche-sur-Yon, Frankrike, 85925
- GSK Investigational Site
-
Nantes, Frankrike, 44093
- GSK Investigational Site
-
Paris, Frankrike, 75014
- GSK Investigational Site
-
-
-
-
-
Ramat Gan, Israel, 52621
- GSK Investigational Site
-
-
-
-
-
Bari, Italia, 70124
- GSK Investigational Site
-
Brescia, Italia, 25123
- GSK Investigational Site
-
Florence, Italia, 50134
- GSK Investigational Site
-
Milan, Italia, 20132
- GSK Investigational Site
-
Milan, Italia, 20162
- GSK Investigational Site
-
Pavia, Italia, 27100
- GSK Investigational Site
-
Pisa, Italia, 56126
- GSK Investigational Site
-
Roma, Italia, 00128
- GSK Investigational Site
-
Torrette AN, Italia, 60126
- GSK Investigational Site
-
Treviso, Italia, 31100
- GSK Investigational Site
-
-
-
-
-
Kanagawa, Japan, 252-0392
- GSK Investigational Site
-
Kanagawa, Japan, 247-8533
- GSK Investigational Site
-
Saitama, Japan, 350-8550
- GSK Investigational Site
-
Tokyo, Japan, 181-8611
- GSK Investigational Site
-
Tokyo, Japan, 162-8666
- GSK Investigational Site
-
-
-
-
-
Beijing, Kina, 100005
- GSK Investigational Site
-
Guangzhou, Kina, 510163
- GSK Investigational Site
-
Hefei, Kina, 230001
- GSK Investigational Site
-
Nanjing, Kina, 210006
- GSK Investigational Site
-
Qingdao, Kina, 266071
- GSK Investigational Site
-
Shanghai, Kina, 200032
- GSK Investigational Site
-
Shenzhen, Kina, 518020
- GSK Investigational Site
-
Wenzhou, Kina, 325000
- GSK Investigational Site
-
-
-
-
-
Groningen, Nederland, 9713 GZ
- GSK Investigational Site
-
Leiden, Nederland, 2333 ZA
- GSK Investigational Site
-
-
-
-
-
Gdansk, Polen, 80-952
- GSK Investigational Site
-
Lodz, Polen, 90-153
- GSK Investigational Site
-
Warsaw, Polen, 01-138
- GSK Investigational Site
-
-
-
-
-
Lisbon, Portugal, 1649-035
- GSK Investigational Site
-
Porto, Portugal, 4099-001
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spania, 08036
- GSK Investigational Site
-
Barcelona, Spania, 08035
- GSK Investigational Site
-
Granada, Spania, 18014
- GSK Investigational Site
-
Pamplona, Spania, 31008
- GSK Investigational Site
-
Zaragoza, Spania, 50009
- GSK Investigational Site
-
-
-
-
-
Birmingham, Storbritannia, B15 2GW
- GSK Investigational Site
-
London, Storbritannia, SE1 7EH
- GSK Investigational Site
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Storbritannia, CB2 2QQ
- GSK Investigational Site
-
-
-
-
-
Malmö, Sverige, SE-205 02
- GSK Investigational Site
-
-
-
-
-
Gwangju, Sør -Korea, 61469
- GSK Investigational Site
-
Seoul, Sør -Korea, 06351
- GSK Investigational Site
-
Seoul, Sør -Korea, 06591
- GSK Investigational Site
-
Seoul, Sør -Korea, 05505
- GSK Investigational Site
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Sør -Korea, 3080
- GSK Investigational Site
-
-
-
-
-
Freiburg im Breisgau, Tyskland, 79106
- GSK Investigational Site
-
Minden, Tyskland, 32429
- GSK Investigational Site
-
-
-
-
-
Budapest, Ungarn, 1023
- GSK Investigational Site
-
-
-
-
Styria
-
Graz, Styria, Østerrike, 8036
- GSK Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participant (male or female) must be 18 years of age or older at the time of signing the informed consent.
- Participants who are >=40 kilogram at Screening Visit 1.
- Participants with a documented diagnosis of EGPA for at least 6 months based on the history or presence of: asthma plus eosinophilia defined as >1.0*10^9/Liter (L) and/or >10 percentage (%) of leucocytes plus at least 2 of the following additional features of EGPA: a biopsy showing histopathological evidence of eosinophilic vasculitis, or perivascular eosinophilic infiltration, or eosinophil-rich granulomatous inflammation, neuropathy, mono or poly (motor deficit or nerve conduction abnormality), pulmonary infiltrates, non-fixed, sino-nasal abnormality, cardiomyopathy (established by echocardiography or magnetic resonance imaging), glomerulonephritis (hematuria, red cell casts, proteinuria), alveolar hemorrhage (by bronchoalveolar lavage), palpable purpura, anti-neutrophil cytoplasmic antibodies positive Myeloperoxidase or Proteinase 3.
- History of relapsing OR refractory disease.
- Participants must be on a stable dose of oral prednisolone or prednisone of >=7.5 mg/day (but not >50 mg/day) or equivalent for at least 4 weeks prior to Baseline (Visit 2).
- If participants receiving immunosuppressive therapy (excluding cyclophosphamide) the dosage must be stable for the 4 weeks prior to Baseline (Visit 2) and during the study.
- A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: Is a woman of non-childbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of <1%.
- Capable of giving signed informed consent
Exclusion Criteria:
- Participants diagnosed with granulomatosis with polyangiitis; previously known as Wegener's granulomatosis or microscopic polyangiitis.
- Participants with organ-threatening EGPA as per EULAR criteria,
- Imminently life-threatening EGPA disease within 3 months prior to Screening (Visit 1).
- A current malignancy or previous history of cancer in remission for less than 12 months prior to Screening.
- Participants with alanine aminotransferase >2*upper limit of normal (ULN) or if participant is on background methotrexate or azathioprine >3*ULN, aspartate aminotransferase >2*ULN or if participant is on background methotrexate or azathioprine >3*ULN, alkaline phosphatase >=2.0*ULN, total bilirubin >1.5*ULN (isolated bilirubin >1.5*ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%), Cirrhosis or current unstable liver or biliary disease per investigator assessment.
- Participants who have severe or clinically significant cardiovascular disease uncontrolled with standard treatment.
- Participants who have known, pre-existing, clinically significant system abnormalities that are not associated with EGPA and are uncontrolled with standard treatment.
- Clinically significant abnormality in the hematological, biochemical or urinalysis screen at Visit 1.
- Chronic or ongoing active infectious disease requiring systemic treatment.
- Participants with a known, pre-existing parasitic infestation within 6 months prior to Screening Visit 1.
- A known immunodeficiency (e.g., human immunodeficiency virus [HIV]).
- Participants that, according to the investigator's medical judgment, are likely to have active coronavirus disease 2019 (COVID-19) infection. Participants with known COVID-19 positive contacts within the past 14 days must be excluded for at least 14 days following the exposure during which the participant must remain symptom-free.
- Participants with a known allergy or intolerance to a monoclonal antibody or biologic therapy or any of the excipients of the investigational products.
- Participants who have a previous documented failure with anti-Interleukin-5 /Interleukin-5 receptor therapy (e.g., mepolizumab, reslizumab, benralizumab). Participants who have received monoclonal antibodies (mAb) and who have not undergone the required washout periods, prior to Visit 1.
- Participants receiving any of the following: Oral corticosteroids: Participant requires an oral corticosteroid dose of >50 mg/day prednisolone/prednisone in the 4-week period prior to Baseline (Visit 2), Intravenous (IV), intramuscular or subcutaneous (SC) corticosteroids in the 4-week period prior to Baseline (Visit 2), Omalizumab within 130 days prior to Screening (Visit 1), Cyclophosphamide (CYC): oral CYC within 4 weeks prior to Baseline (Visit 2) and IV CYC within 3 weeks prior to Baseline (Visit 2), if their total white blood cells is >=4*10^9/L (measured using the local laboratory if necessary), Rituximab within 12 months prior to Screening (Visit 1); in addition, the Participant must have shown recovery of peripheral B-cell count to within the normal range, Tezepelumab and Dupilumab with a washout period of 5 half-lives prior to Screening Visit 1, IV or SC immunoglobulin within 6 months prior to Screening (Visit 1); For China and Japan only within 12 weeks prior to Screening (Visit 1), Interferon-alpha within 6 months prior to Screening Visit 1, Anti-tumor necrosis factor therapy within 12 weeks prior to Screening Visit 1, Anti-CD52 (alemtuzumab) within 6 months prior to Screening Visit 1.
- Participants with QT interval corrected for heart rate according to Fridericia's formula (QTcF) >=450 milliseconds (msec) or QTcF >=480 msec for participants with Bundle Branch Block in the 12-lead ECG central over-read from at Screening Visit 1.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Deltakere som fikk depemokimab+placebo-matchende mepolizumab
|
Depemokimab will be administered Placebo matching to mepolizumab will be administered. |
|
Aktiv komparator: Deltakere som fikk mepolizumab+placebo-matchende depemokimab
|
Mepolizumab will be administered Placebo matching to depemokimab will be administered. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with remission (Birmingham Vasculitis Activity Score [BVAS] =0 and a dose of oral corticosteroid [OCS] less than or equal to [<=] 4 milligram [mg] per day)
Tidsramme: Up to Week 52
|
Participants must be in remission at both Weeks 36 and 52. |
Up to Week 52
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Antall deltakere som oppnår remisjon ved å bruke definisjonen av European League against Rheumatism (EULAR) (BVAS = 0 og OCS <=7,5 mg/dag) i uke 36 og 52
Tidsramme: I uke 36 og 52
|
I uke 36 og 52
|
|
|
Antall deltakere med remisjon (BVAS=0 og OCS <=7,5 mg/dag) innen de første 24 ukene med fortsatt remisjon frem til uke 52
Tidsramme: Frem til uke 52
|
Frem til uke 52
|
|
|
Antall deltakere som oppnår remisjon (BVAS = 0 og OCS ≤ 4 mg/dag) innen de første 24 ukene med vedvarende remisjon til uke 52
Tidsramme: Opptil uke 52
|
Opptil uke 52
|
|
|
Number of participants in each category of accrued duration of remission
Tidsramme: Up to Week 52
|
Total accrued duration of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <= 4 mg/day over the 52-week intervention period. The accrued duration was categorized into zero, >0 to <12 weeks, 12 to <24 weeks, 24 to <36 weeks or more than or equal to (>=) 36 weeks. |
Up to Week 52
|
|
Number of participants with total accrued duration of remission
Tidsramme: Up to Week 52
|
Total accrued duration of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <= 4 mg/day over the 52-week intervention period. |
Up to Week 52
|
|
Time to first EGPA relapse
Tidsramme: Up to Week 52
|
The time to first EGPA relapse will be calculated from the date of first dose of study intervention and start date of the EGPA relapse. |
Up to Week 52
|
|
Number of participants receiving in each category of mean OCS dose during the last 4 weeks of study treatment period (Weeks 49 to 52)
Tidsramme: Weeks 49 to 52
|
Number of participants receiving the mean OCS dose (categorized as 0, >0 to <=4, >4 to <=7.5 or >7.5 mg/day) will be assessed during the last 4 weeks of the study treatment period (Weeks 49 to 52). |
Weeks 49 to 52
|
|
Number of participants in each category of accrued duration of remission according to the EULAR definition of remission (BVAS = 0 plus OCS <=7.5 mg/day) over 52-week intervention period
Tidsramme: Up to Week 52
|
Total accrued duration of remission according to the EULAR definition of remission is the accrued number of weeks where BVAS = 0 plus OCS dose <=7.5 mg/day over the 52 week intervention period categorized as zero weeks; >0 to <12 weeks; 12 to <24 weeks; 24 to <36 weeks or >= 36 weeks. |
Up to Week 52
|
|
Number of participants with total accrued duration of remission according to the EULAR definition of remission
Tidsramme: Up to Week 52
|
Total accrued duration of remission according to the EULAR definition of remission is the accrued number of weeks where BVAS=0 plus OCS <=7.5 mg/day over the 52-week intervention period. |
Up to Week 52
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: GSK Clinical Trials, GlaxoSmithKline
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Autoimmune sykdommer
- Sykdommer i immunsystemet
- Hudsykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Hudsykdommer, vaskulære
- Vaskulitt
- Anti-nøytrofil cytoplasmatisk antistoff-assosiert vaskulitt
- Granulom
- Systemisk vaskulitt
- Hud- og bindevevssykdommer
- Hemic og lymfatiske sykdommer
- Churg-Strauss syndrom
- mepolizumab
Andre studie-ID-numre
- 217102
- 2023-510019-20-00 (Annen identifikator: EU CT Number)
- 2021-005726-15 (Registeridentifikator: EudraCT (EU))
- 2023-510019-20-00 (Registeridentifikator: CTIS (EU))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD for this study will be made available via the Clinical Study Data Request site.
IPD-delingstidsramme
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Tilgangskriterier for IPD-deling
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .